Yael Kenan
Directeur des opérations chez TransPharma Medical Ltd.
Profil
Yael Kenan is currently the Chief Operating Officer at TransPharma Medical Ltd.
Prior to this, she was the Chief Executive Officer at Lacrima Medical Ltd.
from 2013 to 2016.
She also worked as a Principal at Teva Pharmaceutical Industries Ltd.
and as a Member at the National Institute of Health Policy.
From 2016 to 2019, she served as the Vice President-Clinical Affairs at Cellect Biotechnology Ltd.
Dr. Kenan holds an MBA from Technion-Israel Institute of Technology and a doctorate from The Hebrew University of Jerusalem.
Postes actifs de Yael Kenan
Sociétés | Poste | Début |
---|---|---|
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Directeur des opérations | - |
Anciens postes connus de Yael Kenan
Sociétés | Poste | Fin |
---|---|---|
QUOIN PHARMACEUTICALS, LTD. | Directeur Technique/Scientifique/R&D | 31/08/2019 |
Lacrima Medical Ltd.
Lacrima Medical Ltd. Medical SpecialtiesHealth Technology Lacrima Medical Ltd. engages in the development of medical device for the treatment of chronic insomnia. The company was founded in 2013 and is headquartered in Tel Aviv, Israel. | Directeur Général | 01/03/2016 |
National Institute of Health Policy | Corporate Officer/Principal | - |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | - |
Formation de Yael Kenan
Technion-Israel Institute of Technology | Masters Business Admin |
The Hebrew University of Jerusalem | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
Entreprise privées | 4 |
---|---|
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Health Technology |
National Institute of Health Policy | |
Cellect Biotechnology Ltd.
Cellect Biotechnology Ltd. Medical SpecialtiesHealth Technology Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel. | Health Technology |
Lacrima Medical Ltd.
Lacrima Medical Ltd. Medical SpecialtiesHealth Technology Lacrima Medical Ltd. engages in the development of medical device for the treatment of chronic insomnia. The company was founded in 2013 and is headquartered in Tel Aviv, Israel. | Health Technology |